Treatment of brain metastasis: Current status and future directions

Current Opinion in Oncology

Volumn 28, Issue 6, 2016, Pages 502-510

  Ruda, Roberta ^a   Franchino, Federica ^a   Soffietti, Riccardo ^a  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

Brain metastasis; Local treatments; Targeted therapies; Whole brain radiotherapy

Indexed keywords

AFATINIB; CAPECITABINE; DABRAFENIB; ERLOTINIB; GEFITINIB; IPILIMUMAB; LAPATINIB; NAVELBINE; NERATINIB; VEMURAFENIB;

BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; COGNITIVE DEFECT; HUMAN; LOCAL THERAPY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STEREOTACTIC RADIOSURGERY; BRAIN NEOPLASMS; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; RADIOSURGERY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY; TRENDS;

BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; RADIOSURGERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84986193670     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000326     Document Type: Review

References (87)

1. Davis FG, Dolecek TA, McCarthy BJ, et al. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol 2012; 14:1171-1177.
2. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37:745-751.
3. Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008; 70:510-514.
4. Sperduto PW, Kased N, Roberge D, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2012; 82:2111-2117.
5. Subbiah IM, Lei X, Weinberg JS, et al. Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. J Clin Oncol 2015; 33:2239-2245.
6. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494-500.
7. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993; 33:583-590.
8. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996; 78:1470-1476.
9. Vogelbaum MA, Suh JH. Resectable brain metastases. J Clin Oncol 2006; 24:1289-1294.
10. Kamp MA, Rapp M, Bünher J, et al. Early postoperative magnet resonance tomography after resection of cerebral metastases. Acta Neurochir 2015; 157:1573-1580.
11. Patel AJ, Suki D, Hatiboglu MA, et al. Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis. J Neurosurg 2015; 122:1132-1143.
12. Lippitz B, Lindquist C, Paddick I, et al. Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treat Rev 2014; 40:48-59.
13. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multiinstitutional prospective observational study. Lancet Oncol 2014; 15:387-395.
14. Watanabe S, Yamamoto M, Sato Y, et al. Stereotactic radiosurgery for brain metastases: a case-matched study comparing treatment results for patients 80 years of age or older versus patients 65-79 years of age. J Neurosurg 2014; 121:1148-1157.
15. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363:1665-1672.
16. Sperduto PW, Shanley R, Luo X, et al. Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 metastases; poststratified by the Grade Prognostic Assessment (GPA). Int J Radiat Oncol Biol Phys 2014; 90:526-531.
17. Skeie BS, Eide GE, Flatebø M, et al. Quality of life is maintained using Gamma Knife radiosurgery: a prospective study of a brain metastases patient cohort. J Neurosurg 2016; 8:1-18.
18. Kondziolka D, Kano H, HarrisonGL, et al. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article. J Neurosurg 2011; 114:792-800.
19. Marshall DC, Marcus LP, Kim TE, et al. Management patterns of patients with cerebral metastases who underwent multiple stereotactic radiosurgeries. J Neurooncol 2016; 128:119-128.
20. Shultz DB, Modlin LA, Jayachandran P, et al. Repeat courses of stereotactic radiosurgery (SRS), deferring whole-brain irradiation, for new brain metastases after initial SRS. Int J Radiat Oncol Biol Phys 2015; 92: 993-999.
21. Sneed P, Mendez J, Vemer-van den Hoek JGM, et al. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factor. J Neurosurg 2015; 123:373-386.
22. Hanna A, Boggs DH, Kwok Y, et al. What predicts early volumetric edema increase following stereotactic radiosurgery for brain metastases? J Neurooncol 2016; 127:303-311.
23. Chao ST, Ahluwalia MS, Barnett GH, et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int J Radiat Oncol Biol Phys 2013; 87:449-457.
24. Chung C, Metser U, Menard C. Advances in magnetic resonance imaging and positron emission tomography imaging for grading and molecular characterization of glioma. Semin Radiat Oncol 2015; 25:164-171.
25. Hatzoglou V, Yang TJ, Omuro A, et al. A prospective trial of dynamic contrastenhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Neuro Oncol 2016; 18:873-880.
26. Minamimoto R, Saginoya T, Kondo C, et al. Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-methionine PET: visual assessment versus quantitative assessment. PLoS One 2015; 10:0132515.
27. Sneed PK, Suh JH, Goetsch SJ, et al. A multiinstitutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002; 53:519-526.
28. Regine WF, Huhn JL, Patchell RA, et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int J Radiat Oncol Biol Phys 2002; 52:333-338.
29. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998; 280:1485-1489.
30. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus wholebrain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295:2483-2491.
31. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29:134-141.
32. Tsao M, Xu W, Sahgal A. A meta-Analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer 2012; 118:2486-2493.
33. Sahgal A, Aoyama H, Kocher M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-Analysis. Int J Radiat Oncol Biol Phys 2015; 91:710-717.
34. Aoyama H, Tago M, Shirato H, et al. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 9-1 randomized clinical trial. JAMA Oncol 2015; 1:457-464.
35. Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Iny J Radiat Oncol Biol Phys 2007; 68:1388-1395.
36. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009; 10:1037-1044.
37. Brown PD. NCCTG N0574 (Alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. Paper presented at: 2015 ASCO 51st Annual Meeting 2015. Chicago, IL: ; 2015; 44.
38. Soffietti R, Kocher M, Abacioglu U, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 2013; 31:65-72.
39. Amsbaugh MJ, Boling W, Woo S. Tumor bed radiosurgery: an emerging treatment for brain metastases. J Neurooncol 2015; 123:197-203.
40. Brennan C, Yang TJ, Hilden P, et al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys 2014; 88:130-136.
41. Eaton BR, LaRiviere MJ, Kim S, et al. Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neurooncol 2015; 123:103-111.
42. Ling DC, Vargo JA, Wegner RE, et al. Postoperative stereotactic radiosurgery to the resection cavity for large brain metastases: clinical outcomes, predictors of intracranial failure, and implications for optimal patient selection. Neurosurgery 2015; 76:150-156.
43. Minniti G, Esposito V, Clarke E, et al. Multidose stereotactic radiosurgery (9 Gy x 3) of the postoperative resection cavity for treatment of large brain metastases. Int J Radiat Oncol Biol Phys 2013; 86:623-629.
44. Hsieh J, Elson P, Otvos B, et al. Tumor progression in patients receiving adjuvant whole-brain radiotherapy vs localized radiotherapy after surgical resection of brain metastases. Neurosugery 2015; 76:411-420.
45. Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 2013; 15:1429-1437.
46. Gibson E, Monje M. Effect of cancer therapy on neural stem cells: implications for cognitive function. Curr Opin Oncol 2012; 24:672-678.
47. Gondi V, Tome WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. Radiother Oncol 2010; 97:370-376.
48. Suh JH. Hippocampal-Avoidance whole-brain radiation therapy: a new standard for patients with brain metastases? J Clin Oncol 2014; 32:3789-3791.
49. Marsh JC, Herskovic AM, Gielda BT, et al. Intracranial metastatic disease spares the limbic circuit: a review of 697 metastatic lesions in 107 patients. Int J Radiat Oncol Biol Phys 2010; 76:504-512.
50. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during wholebrain radiotherapy for brain metastases (RTOG 0933): a phase II multiinstitutional trial. J Clin Oncol 2014; 32:3810-3816.
51. Lin NU, Lee EQ, Aoyama H, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 2015; 16:270-278.
52. Ellingson BM, Bendszus M, Boxerman J, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol 2015; 17:1188-1198.
53. Morikawa A, Peereboom DM, Thorsheim HR, et al. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro Oncol 2015; 17:289-295.
54. Clarke JL, Pao W, Wu N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010; 99:283-286.
55. Brastianos PK, Carter SL, Santagata S, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 2015; 5:1164-1177.
56. Lin X, DeAngelis LM. Treatment of brain metastases. J Clin Oncol 2015; 33:3475-3484.
57. Mehta MP. Brain metastases: the changing landscape. Oncology (Williston Park) 2015; 29:257-260.
58. Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014; 32:2100-2108.
59. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15:1452-1459.
60. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14:64-71.
61. Freedman RA, Gelman RS, Wefel JS, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol 2016; 34:945-952.
62. Cortes J, Dieras V, Ro J, et al. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUXBreast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol 2015; 16:1700-1710.
63. Bartsch R, Berghoff AS, Vogl U, et al. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis 2015; 32:729-737; First trial on neratinib in brain metastasis from breast cancer.
64. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from nonsmall-cell lung cancer: a prospective trial. Ann Oncol 2004; 15:1042-1047.
65. Wu YL, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in patients with advanced nonsmall-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 2013; 24:993-999.
66. Dempke WC, Edvardsen K, Lu S, et al. Brain metastases in NSCLC: are TKIs changing the treatment strategy? Anticancer Res 2015; 35:5797-5806.
67. Schuler M, Wu YL, Hirsh V, et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol 2016; 11:380-390.
68. Jiang T, Min W, Li Y, et al. Radiotherapy plus EGFR TKIs in nonsmall cell lung cancer patients with brain metastases: an update meta-Analysis. Cancer Med 2016; 5:1055-1065.
69. Zhang I, Zaorsky NG, Palmer JD, et al. Targeting brain metastases in ALKrearranged nonsmall-cell lung cancer. Lancet Oncol 2015; 16:510-521.
70. Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 2015; 33:1881-1888.
71. Johung KL, Yeh N, Desai NB, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 2016; 34:123-129.
72. Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 2014; 74:1023-1028.
73. Rusthoven CG, Doebele RC. Management of brain metastases in ALKpositive non-small-cell lung cancer. J Clin Oncol 2016; 34:2814-2819.
74. Gadgeel SM,Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged nonsmall-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014; 15:1119-1128.
75. Ou SI, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALKrearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 2016; 34:661-668.
76. Besse B, Le Moulec S, Mazié res J, et al. Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res 2015; 21:1896-1903.
77. Ajithkumar T, Parkinson C, Fife K, et al. Evolving treatment options for melanoma brain metastases. Lancet Oncol 2015; 16:486-497.
78. Margolin KA. Brain metastases in melanoma: moving toward curing the incurable. J Oncol Pract 2016; 12:545-546.
79. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13:459-465.
80. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:1087-1095.
81. Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF (V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014; 50:611-621.
82. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30-39.
83. Patel KR, Lawson DH, Kudchadkar RR, et al. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol 2015; 17:1312-1321.
84. Moraes FY, Taunk NK, Marta GN, et al. The rationale for targeted therapies and stereotactic radiosurgery in the treatment of brain metastases. Oncologist 2016; 21:244-251.
85. Wolf A, Zia S, Verma R, et al. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. J Neurooncol 2016; 127:607-615.
86. Xu Z, Lee CC, Ramesh A, et al. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. J Neurosurg 2016; 20:1-9.
87. Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or nonsmall-cell lung cancer and untreated brain metastases: early analysis of a nonrandomised, open-label, phase 2 trial. Lancet Oncol 2016; 17:976-983.